0001209191-20-017553.txt : 20200309 0001209191-20-017553.hdr.sgml : 20200309 20200309214535 ACCESSION NUMBER: 0001209191-20-017553 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200306 FILED AS OF DATE: 20200309 DATE AS OF CHANGE: 20200309 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hindson Benjamin J. CENTRAL INDEX KEY: 0001786391 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39035 FILM NUMBER: 20699750 MAIL ADDRESS: STREET 1: 10X GENOMICS, INC. STREET 2: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 10x Genomics, Inc. CENTRAL INDEX KEY: 0001770787 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 455614458 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: (925) 401-7300 MAIL ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER COMPANY: FORMER CONFORMED NAME: 10X Genomics, Inc. DATE OF NAME CHANGE: 20190315 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-06 0 0001770787 10x Genomics, Inc. TXG 0001786391 Hindson Benjamin J. C/O 10X GENOMICS, INC. 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 1 1 1 0 See Remarks Class A Common Stock 2020-03-06 4 M 0 33750 0.88 A 101250 D Class A Common Stock 2020-03-06 4 S 0 4788 62.8781 D 96462 D Class A Common Stock 2020-03-06 4 S 0 8702 63.7843 D 87760 D Class A Common Stock 2020-03-06 4 S 0 6200 64.849 D 81560 D Class A Common Stock 2020-03-06 4 S 0 3816 65.7358 D 77744 D Class A Common Stock 2020-03-06 4 S 0 2000 66.732 D 75744 D Class A Common Stock 2020-03-06 4 S 0 1300 67.9569 D 74444 D Class A Common Stock 2020-03-06 4 S 0 3099 69.1993 D 71345 D Class A Common Stock 2020-03-06 4 S 0 3845 69.8396 D 67500 D Stock Option (right to buy) 0.88 2020-03-06 4 M 0 33750 0.00 D 2025-10-27 Class A Common Stock 33750 348750 D The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $62.31 to $63.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $63.335 to $64.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $64.34 to $65.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $65.35 to $66.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $66.35 to $67.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $67.50 to $68.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $68.52 to $69.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $69.53 to $70.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. All of the shares subject to the option are fully vested and exercisable as of the date hereof. Chief Scientific Officer and President /s/ Eric S. Whitaker, as Attorney-in-Fact 2020-03-09